S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: World shares mixed after Wall Street retreat deepens
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
US consumer confidence tumbles in September as American anxiety about the future grows
NASDAQ:INDP

Indaptus Therapeutics (INDP) Stock Forecast, Price & News

$2.78
+0.29 (+11.65%)
(As of 09/26/2023 ET)
Compare
Today's Range
$2.52
$2.85
50-Day Range
$1.75
$3.95
52-Week Range
$1.25
$4.08
Volume
24,648 shs
Average Volume
25,028 shs
Market Capitalization
$23.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Indaptus Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
331.7% Upside
$12.00 Price Target
Short Interest
Healthy
0.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.65mentions of Indaptus Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$142,052 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.92) to ($1.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.66 out of 5 stars

Medical Sector

118th out of 963 stocks

Pharmaceutical Preparations Industry

36th out of 450 stocks


INDP stock logo

About Indaptus Therapeutics (NASDAQ:INDP) Stock

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

INDP Price History

INDP Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Indaptus Therapeutics (NASDAQ:INDP) Trading Up 7.3%
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Maxim Group Remains a Buy on Indaptus Therapeutics (INDP)
What 4 Analyst Ratings Have To Say About Indaptus Therapeutics
See More Headlines
Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INDP Company Calendar

Last Earnings
8/14/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INDP
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+331.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.98 per share

Miscellaneous

Free Float
6,124,000
Market Cap
$23.35 million
Optionable
Not Optionable
Beta
1.04
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Jeffrey A. MecklerMr. Jeffrey A. Meckler (Age 56)
    CEO & Director
    Comp: $888.32k
  • Mr. Walt Addison Linscott Esq. (Age 62)
    Chief Operating Officer
    Comp: $666.63k
  • Dr. Michael J. Newman Ph.D. (Age 67)
    Founder, Chief Scientific Officer & Director
  • Mr. Nir Sassi (Age 47)
    CFO, Sec. & Treasurer
  • Dr. Roger J. Waltzman M.B.A. (Age 55)
    M.D., Chief Medical Officer













INDP Stock - Frequently Asked Questions

Should I buy or sell Indaptus Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indaptus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INDP shares.
View INDP analyst ratings
or view top-rated stocks.

What is Indaptus Therapeutics' stock price forecast for 2023?

1 equities research analysts have issued 12-month price objectives for Indaptus Therapeutics' stock. Their INDP share price forecasts range from $12.00 to $12.00. On average, they anticipate the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 331.7% from the stock's current price.
View analysts price targets for INDP
or view top-rated stocks among Wall Street analysts.

How have INDP shares performed in 2023?

Indaptus Therapeutics' stock was trading at $1.45 on January 1st, 2023. Since then, INDP shares have increased by 91.7% and is now trading at $2.78.
View the best growth stocks for 2023 here
.

When is Indaptus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our INDP earnings forecast
.

How were Indaptus Therapeutics' earnings last quarter?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.19.

What is Indaptus Therapeutics' stock symbol?

Indaptus Therapeutics trades on the NASDAQ under the ticker symbol "INDP."

Who are Indaptus Therapeutics' major shareholders?

Indaptus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Investment House LLC (1.29%) and Strategy Asset Managers LLC (0.54%). Insiders that own company stock include Boyan Vesselinov Litchev, Glen R Anderson, Jeffrey A Meckler, Michael James Newman and Walt Addison Linscott.
View institutional ownership trends
.

How do I buy shares of Indaptus Therapeutics?

Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Indaptus Therapeutics' stock price today?

One share of INDP stock can currently be purchased for approximately $2.78.

How much money does Indaptus Therapeutics make?

Indaptus Therapeutics (NASDAQ:INDP) has a market capitalization of $23.35 million. The company earns $-14,320,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How can I contact Indaptus Therapeutics?

Indaptus Therapeutics' mailing address is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. The official website for the company is intecpharma.com. The company can be reached via phone at (646) 427-2727, via email at will.oconnor@sternir.com, or via fax at 972-2586-9176.

This page (NASDAQ:INDP) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -